Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Medical Device

Microport EP Medtech’s Pressure Monitoring Catheter Approved by NMPA

Fineline Cube Dec 5, 2022

Shanghai Microport EP Medtech Co., Ltd’s disposable pressure monitoring magnetic positioning radiofrequency catheter has been...

Company Drug

Henlius Biotech Doses First Patient in Phase I Study for HLX60 in China

Fineline Cube Dec 5, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing of a Phase I...

Company Drug

Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia

Fineline Cube Dec 5, 2022

A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...

Company Drug

Hansoh’s EGFR Inhibitor Ameile Filed for EMA Review by Partner EQRx

Fineline Cube Dec 5, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a market filing for its...

Company Drug

Sinocelltech’s SCTV01C Vaccine Included in China’s Emergency Use Program

Fineline Cube Dec 5, 2022

China-based Sinocelltech Group Ltd (SHA: 688520) announced the inclusion of its recombinant novel coronavirus alpha+beta...

Company Drug

Lynk Pharmaceuticals Doses First Patient in Phase II Study for LNK01003

Fineline Cube Dec 5, 2022

China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical...

Company Deals

Lavamed Secures USD 40M in Angel and Series A Financing Rounds

Fineline Cube Dec 5, 2022

Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...

Company Drug

Innovent Biologics Doses First Volunteer in Orismilast Phase I Study

Fineline Cube Dec 5, 2022

China-based Innovent Biologics Inc., (HKG: 1801) and Denmark-based partner Union Therapeutics A/S revealed that a...

Company Drug

Daiichi Sankyo Doses First Patient in Global Phase III TROPION-Lung08 Study

Fineline Cube Dec 5, 2022

Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced the first patient dosed in the global multi-center...

Company Deals

Tsingke Biotech Secures RMB 400M Series B Financing for Expansion

Fineline Cube Dec 5, 2022

Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...

Company Deals

China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia

Fineline Cube Dec 5, 2022

China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...

Company Deals

SAFE Raises RMB 500M in Series D Financing to Expand CRO Services

Fineline Cube Dec 5, 2022

Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...

Company Medical Device

Peijia Medical Enrolls First Patient in GeminiOne TEER System Study

Fineline Cube Dec 5, 2022

China’s Peijia Medical Ltd (HKG: 9996) announced first patient enrollment in a multi-center clinical study...

Company Drug

NMPA Approves Henlius’ HLX04 Biosimilar for Lung and Colorectal Cancer

Fineline Cube Dec 2, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Shanghai Henlius Biotech’s (HKG: 2696)...

Company Deals

Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...

Company Drug

Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials

Fineline Cube Dec 2, 2022

China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...

Company Deals

Eli Lilly Ends License for Innovent’s Tyvyt Outside China

Fineline Cube Dec 2, 2022

Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...

Company Deals

Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China

Fineline Cube Dec 2, 2022

Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...

Company Deals Digital

Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine

Fineline Cube Dec 2, 2022

China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...

Company Deals

Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China

Fineline Cube Dec 2, 2022

China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...

Posts pagination

1 … 533 534 535 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.